Drug
Amcasertib clinical trials
Also written BBI503 and BB503.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 4 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Sumitomo Pharma America, Inc. (7) · Sumitomo Pharma Co., Ltd. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses amcasertib is read from its arms, and is right about nine times in ten.
Testing it · 8
- A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular CarcinomaCompletedPhase 1/2Sumitomo Pharma America, Inc.NCT02279719Written as BBI503
- A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 ElevationTerminatedPhase 2Sumitomo Pharma America, Inc.NCT02432690Written as BBI503
- A Study of BBI503 in Adult Patients With Advanced Solid TumorsCompletedPhase 1Sumitomo Pharma America, Inc.NCT01781455Written as BBI503
- A Study of BBI503 in Adult Patients With Advanced Hepatobiliary CancerCompletedPhase 2Sumitomo Pharma America, Inc.NCT02232633Written as BBI503
- A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal TumorsTerminatedPhase 2Sumitomo Pharma America, Inc.NCT02232620Written as BBI503
- A Study of BBI503 in Adult Patients With Advanced Urologic MalignanciesWithdrawnPhase 2Sumitomo Pharma America, Inc.NCT02232646Written as BBI503
- A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid TumorsCompletedPhase 1Sumitomo Pharma America, Inc.NCT02432326Written as BBI503
- A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular CarcinomaCompletedPhase 1Sumitomo Pharma Co., Ltd.NCT02354898Written as BBI503
Given in every arm · 1 — amcasertib is usual care beside what is tested
Codes
What other systems call amcasertib · ClinicalTrials.gg INT016678
- UNII (FDA) GLY8ABW25VAMCASERTIBConfirmed FDA, Wikidata
- Wikidata Q27279170amcasertibConfirmed FDA, Wikidata
- NCI Thesaurus C104745AmcasertibOne source FDA
- DrugBank DB14866One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | GLY8ABW25V | AMCASERTIB | Confirmed FDA, Wikidata |
| Wikidata | Q27279170 | amcasertib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C104745 | Amcasertib | One source FDA |
| DrugBank | DB14866 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.